The role of biomarkers as an alternative and completion of the diagnostic and therapeutic pathway in patients with aortic stenosis (RCD code: VIII)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2016, Vol 2, Issue 7
Abstract
Aortic stenosis (AS) is the most frequent type of valvular heart disease. Clinically, it presents as calcific and congenital AS. Calcific AS is often age dependent and affects 2–7% of people over 65 years of age. Many clinical studies proved high correlation between age and the prevalence of calcific aortic stenosis. According to todays’ knowledge, AS presents not only as simple degenerative disease of the valve, but as an active inflammatory and proliferative process. Better control and evaluation of risk factors might decelerate progression of the disease. It is necessary to increase the knowledge about risk factors and early markers of AS. Echocardiography is the method of choice in the diagnostic course and evaluation of stenosis grade and disease progression, but the role of biomarkers is becoming more and more significant among the clinical evaluation of patients and has been already mentioned in The European Society of Cardiology (ESC) guidelines on the management of valvular heart disease in patients qualified for Aortic Valve Replacement (AVR) with severe, asymptomatic AS, preserved ejection fraction and normal exercise stress test results. The natriuretic peptides level increase at the follow-up measurements is an important co-factor in decision-making. This review article analyses and summarizes the most important research and correlation between calcific aortic valve disease and the biomarkers. The potential clinical implementation of fourteen biomarkers has been reviewed. Echocardiography depends on the operator experience and imaging quality, therefore biomarkers could contribute important information to patients’ diagnosis and follow-up.
Authors and Affiliations
Jakub Podolec, Łukasz Niewiara, Bartłomiej Guzik, Krzysztof Żmudka
Keywords
Related Articles
- EP ID EP245346
- DOI 10.20418/jrcd.vol2no7.218
- Views 93
- Downloads 0
A 23‑year‑old woman with Marfan syndrome and spine deformity (RCD code: I-2A.1)
Marfan syndrome is one of the most common heritable connective tissue disorders that is caused by various mutations of the Fibrillin-1(FBN1) gene. The cardinal features of Marfan syndrome are aortic root dilatation and e...
Brugada syndrome: 2017 update. (RCD code: V-1A.1)
N/A
Electrocardiographic abnormalities in patients with pulmonary sarcoidosis (RCD code: III)
Sarcoidosis is a systemic inflammatory disease characterized by the presence of noncaseating granulomas. Etiology of the disease remains unknown. From 3.7% to 54.9% patients with extra‑cardiac sarcoidosis have asymptomat...
2nd Symposium on Rare Cardiovascular Diseases – ESC Munich 2012: Chairperson’s Perspective
In response to interest generated by the 1st Satellite Symposium on Rare Cardiovascular Diseases (Paris, ESC 2011), a session devoted to managing patients with rare cardiovascular diseases was organized this year again,...
Report from the European Society of Cardiology Congress 2015 in London
At least for us, the ESC Congress 2015 in London was different from the previous ones as we did not organize Satellite Symposium on rare cardiovascular diseases. It is not that we did not want to, on the contrary we trie...